Microbiome Therapeutics Market Analysis by Type {Fecal Microbiota Transplantation (FMT), and Microbiome Drugs}; by Application {Diabetes, Crohn’s Disease, Clostridium Difficile Infection (CDI), Multiple Sclerosis, Rheumatoid Arthritis, and Others}; and by Product (Prebiotics, Probiotics, Symbiotics, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035

  • Report ID: 2852
  • Published Date: Mar 24, 2023
  • Report Format: PDF, PPT

Companies Dominating the Microbiome Therapeutics Landscape

    • YSOPIA Bioscience
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • 4D pharma plc
    • Enterome
    • BiomX Inc.
    • Ferring International Center S.A.
    • Vedanta Biosciences, Inc.
    • Seres Therapeutics, Inc.
    • Assembly Biosciences, Inc.
    • Synlogic
    • Finch Therapeutics Group, Inc. 

Browse Key Market Insights with Data Illustration:


In The News

  • Enterome has introduced the world's first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics therapeutic cancer vaccine, at the American Society of Clinical Oncology (ASCO) Annual Meeting.

  • Ferring International Center S.A. has received approval from the U.S. FDA for REBYOTA (fecal microbiota, live-jslm). It is a novel first-in-class microbiota-based live biotherapeutic denoted for the inhibition of recurrence of Clostridioides difficile infection (CDI) in individuals of 18 years of age and older, following antibiotic treatment for recurrent CDI.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 2852
  • Published Date: Mar 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rise in the investments of microbiome modulators, worldwide growing prevalence of diabetes, and an increase in the development of novel microbiome are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 24% over the forecast period, i.e., 2023-2035.

Risk of failure of the concerned research projects, and stringent regulatory guidelines imposed by the government of nations are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are YSOPIA Bioscience, 4D pharma plc, Enterome, BiomX Inc., Ferring International Center S.A., Vedanta Biosciences, Inc., Seres Therapeutics, Inc., Finch Therapeutics Group, Inc., and others.

The company profiles are selected based on the revenues generated from segments, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, application, product, and by region.

The diabetes segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying